Ultime notizie per Eledon Pharma (NASDAQ:ELDN) Azioni

Eledon Pharma

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals Inc

Former President Donald Trump has reiterated his commitment to imposing tariffs on cars imported from China and Mexico, aiming to protect American automotive jobs.
What Happened: During an interview with Patrick Bet-David released on Thursday, Trump emphasized the critical role these tariffs would play in safeguarding the U.S. auto industry.
&#8220;I hope the union workers, auto workers understand that I saved their jobs,&#8221; he said.
Trump highlighted a massive car manufacturing plant in Mexico, which he described as potentially one of the largest in the world. He expressed concerns that vehicles from this plant could inundate the U.S. market, leaving little room for American-made cars.
&#8220;That would mean that our car industry is wiped out,&#8221; Trump said.
See Also: <a href="https://www.benzinga.com/news/24/10/41328039/as-elon-musk-unveils-cybercab-uber-ceo-weighs-in-on-robotaxi-competiton-from-waymo-tesla-dont-think?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As Elon Musk Unveils Cybercab, Uber CEO Weighs In On Robotaxi Competiton From Waymo, Tesla: &#8216;Don&#8217;t Think This Is Going To Be A Winner-Take-All Marketplace&#8217;</a>
Why It Matters: In September, Trump <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">proposed a 200% tariff</a> on vehicles produced by alleged Chinese factories in Mexico, as reported in a town hall event in Flint, Michigan. He warned that if Vice President Kamala Harris were elected, the U.S. auto industry could collapse within two to three years due to electric vehicle production shifting to China.
Additionally, during a <a href="https://www.benzinga.com/general/politics/24/10/41279272/donald-trump-pushes-tariffs-on-chinese-cars-in-detroit-visit-vows-to-revamp-industry">visit to the Detroit Economic Club</a> in October, Trump reiterated his commitment to tariffs on Chinese cars, vowing to revamp the industry. He also commented on economic indicators, although some of his statements on inflation and interest rates were inaccurate.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41369986/lucid-stock-is-tumbling-wednesday-whats-driving-the-action?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lucid Stock Is Tumbling Wednesday: What&#8217;s Driving The Action?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

News

General

Trump Defends His Plans To Impose 200% Tariffs On Cars Imported From China, Mexico: 'Hope Union Workers Understand That I Saved Their Jobs'

Amid ongoing global economic recovery efforts, Kristalina Georgieva, Managing Director of the International Monetary Fund, has issued a cautionary note regarding persistent challenges such as high debt and low growth. Her remarks come as the U.S. and EU implement rate cuts to tackle inflation.
What Happened: Georgieva highlighted that despite progress, governments are increasingly reliant on borrowing, which, coupled with &#8220;anemic growth,&#8221; complicates debt management. She praised central banks for their inflation control efforts but noted uneven benefits across regions, with some still facing high prices and related unrest, CNBC <a href="https://www.cnbc.com/2024/10/17/imf-chief-warns-low-growth-and-high-debt-weigh-on-global-economy.html">reported</a> on Friday.
"It's not yet time to celebrate," she said.
"When we look into the challenges ahead of us, the biggest one is low growth, high debt. This is where we can and must do better.&#8221;
Georgieva&#8217;s comments precede the 2024 annual meetings of the IMF and World Bank Group in Washington, D.C., where global economic issues will be discussed. She also pointed out that international trade is no longer the &#8220;engine of growth&#8221; it once was, citing restrictive policies and <a href="https://www.benzinga.com/news/24/09/40914629/china-warns-eu-tariffs-on-evs-will-harm-trade-with-germany">U.S.-EU tariffs against China</a> as potential risks. Additionally, she expressed concern over geopolitical tensions, particularly in the Middle East, affecting global financial stability.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Georgieva&#8217;s comment arrived a day after the European Central Bank (ECB) <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41382372/ecb-slashes-rates-again-will-jerome-powell-take-this-as-cue-for-another-fed-rate-"> cut interest rates</a> for the third time this year to stimulate a sluggish economy, shifting focus from inflation control to economic growth. This move follows the Federal Reserve&#8217;s 50 basis point rate cut in September, marking a significant policy shift as both regions tackle economic challenges.
Meanwhile, the U.S. faces a staggering debt situation, with estimates suggesting a<a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40368118/true-us-debt-is-175-trillion-former-coinbase-cto-on-unpayable-crisis"> true national debt </a>of $175 trillion when accounting for entitlements like Social Security and Medicare. This escalating debt underscores the urgency of addressing fiscal challenges.
In China, the government is reportedly considering issuing $850 billion in<a href="https://www.benzinga.com/markets/asia/24/10/41324527/as-chinas-stimulus-hype-wanes-beijing-reportedly-weighs-850b-special-treasury-bonds-to-stimulate-eco"> special treasury bonds</a> to stimulate its slowing economy and manage local debt. These developments highlight the global nature of economic challenges and the varied approaches being taken to address them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41372368/mark-cuban-battles-former-trump-advisor-for-suggesting-a-child-could-do-american-auto-workers-job-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Battles Former Trump Advisor Over Ex-President&#8217;s Comments On American Auto Workers: &#8216;He Still &nbsp;Thinks It&#8217;s 1965&#8217; (UPDATED)</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Macro Economic Events

Global

Economics

As US Tackles Inflation With Rate Cuts, IMF MD Sounds Alarm: 'Not Yet Time To Celebrate' Amid Looming Low Growth, High Debt

The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Friday, Oct. 18.</a>
Analysts expect the Cincinnati, Ohio-based bank to report quarterly earnings at $1.90 per share, up from $1.83 per share in the year-ago period. Procter &amp; Gamble projects to report revenue of $21.91 billion for the recent quarter, compared to $19.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 30, Procter &amp; Gamble reported fourth-quarter FY24 sales of $20.53 billion (flat Y/Y), missing the analyst consensus estimate of $20.74 billion.
Procter &amp; Gamble shares fell 0.1% to close at $172.28 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5890a92043eaaa0001d69b01/linda-bolton%20weiser">DA Davidson analyst Linda Bolton Weiser</a> maintained a Neutral rating with a price target of $159 on Oct. 15. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Lauren Lieberman downgraded the stock from Overweight to Equal-Weight with a price target of $163 on Sept. 30. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Andrea Teixeira maintained an Overweight rating and increased the price target from $179 to $186 on Sept. 19. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow initiated coverage on the stock with a Buy rating and a price target of $189 on July 23. This analyst has an accuracy rate of 65%.</li>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and raised the price target from $157 to $161 on July 22. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying PG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="482" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png" alt="" class="wp-image-602127" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158.png 1365w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Procter & Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans,Benson &amp; Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantially similar proposed plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM).
Under the Proposed Plan, if ultimately approved and implemented, RBH, ITL and JTIM (the Companies) would pay an aggregate settlement amount of CAD 32.5 billion (approximately USD 23.5 billion). This amount would be funded by an upfront payment equal to the Companies' cash and cash equivalents on hand in Canada plus certain court deposits (subject to an aggregate withholding of CAD 750 million (approximately USD 540 million) for working capital inclusive of cash pledged as collateral) and annual payments based on a percentage of the Companies' net income after taxes (excluding that generated by certain non-combustible products including heat-not-burn, e-vapor and nicotine pouch products) until the aggregate settlement amount is paid. As stated in the Proposed Plan, the issue of allocation of the CAD 32.5 billion aggregate settlement as between the Companies in the CCAA proceedings remains unresolved.
"After years of mediation, we welcome this important step towards the resolution of long-pending tobacco product-related litigation in Canada," said Jacek Olczak, Chief Executive Officer of PMI. "Although important issues with the plan remain to be resolved, we are hopeful that this legal process will soon conclude, allowing RBH and its stakeholders to focus on the future."

Legal

Philip Morris, Imperial Tobacco, JTI-Macdonald Face $23.5B Settlement in Canada Tobacco Lawsuits

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=3e1a02702fd6e8744473a752dd19c5f5">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced the opening of a new headquarters and technical hub in Lisbon, Portugal to further support its growing EMEA operations and offices in London, Paris, Munich, and Dubai. Portugal already represents a growing Cloudflare team.
Today, Cloudflare's network currently spans 58 cities in Europe, including Lisbon, Portugal, which was announced in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.cloudflare.com%2Famsterdam-to-zhuzhou-cloudflare-global-network%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=2016&amp;index=2&amp;md5=89c437ed99560575fd137ba7cd354fa5">2016</a>. Cloudflare announced its first office in Lisbon in 2019. Since establishing an office in the region, the company has grown from 14 employees to more than 350 in Portugal. Cloudflare plans to significantly increase its presence in Lisbon over the coming years.
Cloudflare celebrated the official opening of its new office with a ribbon cutting ceremony, followed by a reception attended by Portugal's Minister of Economy, Mr. Pedro Reis, along with other Portuguese officials. Top Cloudflare executives were also in attendance, including Cloudflare co-founder and CEO Matthew Prince, and John Graham-Cumming, CTO &amp; Head of the Lisbon office, which he opened in July 2019.

Government

Regulations

Cloudflare Expands European Operations With New Lisbon Headquarters, Plans Major Workforce Growth

Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) will release earnings results for its third quarter, before the<a href="https://www.benzinga.com/quote/SLB/earnings"> opening bell on Friday, Oct. 18.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at 88 cents per share, up from 71 cents per share in the year-ago period. SLB projects to report revenue of $9.25 billion for the quarter, compared to $7.58 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, SLB agreed to sell its interests in Palliser Block.
SLB shares gained 0.7% to close at $43.99 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580874cb846faa000106ac9d/david-anderson">Barclays analyst David Anderson</a> maintained an Overweight rating and cut the price target from $67 to $63 on Oct. 16. This analyst has an accuracy rate of 63%.</li>
<li>Stifel analyst Stephen Gengaro maintained a Buy rating and cut the price target from $65 to $62 on Oct. 11. This analyst has an accuracy rate of 60%.</li>
<li>BMO Capital analyst Philip Jungwirth maintained an Outperform rating and cut the price target from $60 to $58 on Oct. 10. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Arun Jayaram maintained an Overweight and cut the price target from $64 to $60 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Connor Lynagh maintained an Overweight rating and slashed the price target from $65 to $60 on Sept. 16. This analyst has an accuracy rate of 60%.</li>
</ul>
Considering buying SLB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png" alt="" class="wp-image-602108" style="width:705px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157.png 1338w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

SLB Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mostly higher on Thursday, with the Dow Jones index climbing to a new record close following the release of economic data.
U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12. U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise. The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.
Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) shares jumped around 9.8% on Thursday following better-than-expected third-quarter earnings and strong fourth-quarter guidance
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and real estate stocks recording the biggest losses on Thursday. However, energy and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 161 points to 43,239.05 on Thursday. The S&amp;P 500 slipped 0.02% to 5,841.47, while the Nasdaq Composite rose 0.04% at 18,373.61 during Thursday's session.
Investors are awaiting earnings results from American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 71.5, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 69.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

TSMC, Strong Economic Data Push Dow To Fresh Record High: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) to report quarterly earnings at $3.28 per share on revenue of $16.67 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Express shares gained 1.8% to $290.91 in after-hours trading.</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion. The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year. Netflix shares climbed 5.1% to $722.35 in the after-hours trading session.</li>
<li>Analysts are expecting The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.90 per share on revenue of $21.91 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 0.1% to $172.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) posted better-than-expected third-quarter financial results. The company also said it obtained regulatory clearance in South Korea for the da Vinci 5 surgical system in October. Intuitive Surgical shares climbed 6.1% to $502.80 in the after-hours trading session.</li>
<li>Analysts expect Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to report quarterly earnings at 88 cents per share on revenue of $9.25 billion before the opening bell. SLB shares rose 0.4% to $44.16 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

ISRG

NFLX

Netflix, American Express And 3 Stocks To Watch Heading Into Friday

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) founder Michael Saylor encouraged those who doubt the upside potential of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to go short on the company's stock, assuring that it would never sell the cryptocurrency.
What happened: During an interview with journalist Madison Reidy that aired Thursday, Saylor asked skeptics to "love" MicroStrategy if they really "hate" Bitcoin.
"We&#8217;re the perfect instrument to short because I promise you, I won&#8217;t sell it. We&#8217;re going to be leveraged long on Bitcoin," said Saylor, one of the most passionate advocates of the cryptocurrency.
&#8220;I want you to love us if you really hate BTC.&#8221;
Saylor said as a company, MicroStrategy has been consistent and transparent in its policy of buying and holding on to Bitcoin, and it was up to market participants to decide if they wanted to buy, sell, or short their shares.
"When I was a younger man I would have been concerned about people shorting my stock but now I&#8217;m not," Saylor added.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41373332/donald-trump-backed-world-liberty-financial-off-to-a-slow-start-raises-just-4-of-the-token">Donald Trump-Backed World Liberty Financial Off To A Slow Start — Raises Just 4% Of The Token Fundraising Target</a>
Why It Matters: Saylor&#8217;s remarks came amid MicroStratgy&#8217;s audacious Bitcoin gambit, which has transformed the software development firm into a proxy for the world&#8217;s greatest digital asset.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40306998/since-embracing-bitcoin-4-years-ago-michael-saylors-microstrategy-has-outperformed-warren-">adopted Bitcoin as its primary reserve asset</a> in 2020, becoming the first publicly listed company to pursue this strategy, and hasn't looked back since then. Today, it holds over $17 billion of its total capital in Bitcoin, <a href="https://bitcointreasuries.net/">according</a> to bitcointreasuries.net.
Saylor projects that by 2045, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40916462/michael-saylor-bitcoin-to-hit-13m-by-2045-will-get-us-to-a-different-place#:~:text=Michael%20Saylor%3A%20Bitcoin%20To%20Hit,To%20A%20Different%20Place'%20%2D%20Benzinga">Bitcoin will constitute 7% of global financial capital</a>, implying a $13 million price per Bitcoin.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Michael Saylor: Why MicroStrategy's Bitcoin funding is NOT a glitch" width="500" height="281" src="https://www.youtube.com/embed/eThjo9wYoF0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: At the time of writing, Bitcoin was exchanging hands at $67,931.57, up 0.98% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of MicroStrategy closed down 0.35% to $193.42 during Thursday's regular trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372654/peter-schiff-questions-trump-inspired-bitcoin-pump-one-of-the-promises-he-did-not-make-was">Peter Schiff Question &#8216;Trump-Inspired&#8217; Bitcoin Pump: &#8216;One Of The Promises He Did Not Make Was To Buy Any&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Boss Michael Saylor Taunts Bitcoin Doubters, Challenges Them To Short Company's Stock: 'I Want You To Love Us If You Really Hate BTC'

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo is providing riders who <a href="https://www.benzinga.com/news/24/06/39494723/waymo-autonomous-rides-now-available-to-everyone-in-san-francisco-heres-how-you-can-enjoy-driverless">avail an autonomous ride</a> to select transit stations in San Francisco and the Peninsula $3 credit in a bid to promote public transportation, the company said on Thursday.
What Happened: Waymo will credit $3 to riders&#8217; accounts if they take an autonomous ride to or from eligible Bay Area transit stations. These credits can be used for future rides.
The program started on Oct. 17 and will go on till Nov.15. The credits can be used until Dec. 31, according to a statement from Waymo. 
&#8220;By offering electric rides on demand and improving access to public transit, Waymo One is making daily travel more sustainable and convenient,&#8221; said Adam Lenz, Head of Sustainability and Environment at Waymo.
Why It Matters: Waymo currently operates a fleet of all-electric vehicles that have been customized to enable autonomous driving. The company is delivering over 100,000 paid autonomous rides every week to the public, the company said on Thursday.
Automotive research firm&nbsp;S&amp;P Global Mobility&nbsp;said in September that it deems&nbsp;<a href="https://www.benzinga.com/news/24/09/40792410/us-autonomous-vehicle-sales-to-hit-230k-by-2034-after-progress-resumes-at-alphabets-waymo-gms-cruise" target="_blank" rel="noreferrer noopener">Waymo to be the frontrunner&nbsp;</a>in the field of autonomous vehicles in the U.S.&nbsp;
&nbsp;In July, Alphabet committed&nbsp;to a new multiyear&nbsp;<a href="https://www.benzinga.com/news/24/07/39924838/alphabet-commits-to-another-5b-investment-in-waymo-tesla-ceo-elon-musk-takes-jibe-at-cash-burn-in-un" target="_blank" rel="noreferrer noopener">investment of $5 billion into Waymo</a>&nbsp;to help the company "continue to build the world's leading autonomous driving technology company."
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX&#8217;s Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them:&#8217; Will Offer 10X Increase In Bandwidth And Reduced Latency</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

GOOG

GOOGL

Waymo Offers Free Credits To Riders Traveling To Select Transit Stations In The Bay Area: Here's How Much You Can Get

Coca-Cola Europacific Partners plc (&quot;CCEP&quot; or the &quot;Company&quot;) today confirms notification of transfer of UK listing category from the Equity Shares (Transition) category to the Equity Shares (Commercial Companies) category of the Official List

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-Cola Europacific Partners To Shifts To Commercial Companies Category, Paving The Way For FTSE Index Eligibility

NYCB

Reported Earlier, Flagstar Bank, Subsidiary of New York Community Bancorp, Cuts 8% of Workforce In Strategic Transformation And Cost-Cutting Initiative

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Econ #s

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit. However, there are some penny stocks that, while still containing risk, are much more likely to see real success in the future, potentially leading to significant financial gains for investors.



These three penny stocks have solid foundations and are poised to do great things within their respective markets. While they are still accompanied by risk, these stocks will likely graduate to the next level in a matter of time due to the demand surrounding their products and favorable market shifts.



Let&rsquo;s learn about the events and projected successes that showcase these stocks&rsquo; exciting potential to grow tremendously in the coming years.



<h2>Tilray Brands (TLRY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/tlry_tilray1600-2-300x169.png" alt="Close view of Tilray (TLRY) logo on a smart phone. Tilray specializes in cannabis research, cultivation, processing and distribution. TLRY stock"><div>Source: Lori Butcher / Shutterstock.com</div></div>Following the announcement that the Drug Enforcement Administration in May proposed the <a href="https://www.morganlewis.com/blogs/asprescribed/2024/05/from-prohibition-to-prescription-dea-issues-proposed-rule-to-reschedule-marijuana#:~:text=From%20Prohibition%20to%20Prescription%3A%20DEA%20Issues%20Proposed%20Rule%20to%20Reschedule%20Marijuana,-By%20Kathleen%20M&amp;text=On%20May%2021%2C%202024%2C%20the,Controlled%20Substances%20Act%20(CSA).">rescheduling of marijuana</a> to a Schedule Three controlled substance, there has been a lot of buzz in the cannabis industry. 



An established brand like Tilray Brands (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlry-stock-quote/">TLRY</a>) would be in a prime position to benefit and profit exponentially from an expansion into the U.S. market.



Tilray is a Canadian cannabis producer that has established a name for itself within the market. So far this year, Tilray has seen <a href="https://ir.tilray.com/news-releases/news-release-details/tilray-brands-inc-reports-q3-fiscal-2024-financial-results">decent success</a>, reporting a 30% revenue increase year-over-year and encouraging sales in all three of its primary business segments: cannabis, distribution and alcohol.



The company has excellent diversity within its revenue streams and is in a phase of strong emphasis on making new acquisitions to expand its business. While this strategy has garnered some success, it has also caused trouble for Tilray this year. One of the companies in Tilray&rsquo;s portfolio <a href="https://www.forbes.com/sites/dariosabaghi/2024/04/29/cannabis-company-medmen-goes-bankrupt-with-411-million-in-liabilities/">declared bankruptcy</a> in April, causing a considerable snag in Tilray&rsquo;s U.S. expansion.



Tilray will need to do some serious damage control and cover much more ground to reach the U.S. market in the capacity it had initially planned. However, the company is already reassessing and implementing an updated expansion plan. Rescheduling from the DEA will create a massive opportunity for Tilray, and investors can easily take advantage of it now.



<h2>Rigel Pharmaceuticals (RIGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/syringe-needle-biopharma-1600-1-300x169.jpg" alt="A syringe with a safety cap and a surgical mask laid out on a blank background"><div>Source: shutterstock.com/Michele Ursi</div></div>Rigel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rigl-stock-quote/">RIGL</a>) is an up-and-coming biopharma company with an exciting collection of treatments for hematologic disorders and cancer. The conditions that Rigel sets out to treat have little to no available therapies and are in high demand.



Rigel has two prized sellers on the market right now that have already been granted FDA approval. Tavalisse treats chronic immune thrombocytopenia, or ITP, and Rezlidhia treats acute myeloid leukemia, or AML. Tavalisse makes up most of the<a href="https://www.rigel.com/news-media/press-releases/detail/385/rigel-reports-first-quarter-2024-financial-results-and"> company&rsquo;s revenue</a>, accounting for $21.1 million in net product sales last quarter, but Rezlidhia still contributed sales of $4.9 million.



Rigel has significantly reduced its net loss from a year ago, reporting a $5.3 million difference. The company also continues to share exciting news from the pipeline, including a presentation it recently gave at the 2024 ASCO Annual Meeting that <a href="https://www.rigel.com/news-media/press-releases/detail/388/rigel-highlights-new-data-in-three-poster-presentations-at">showcased strong data</a> showcasing the effectiveness of Rezlidhia in treating a series of difficult conditions.



The other exciting news Rigel announced this year is the appointment of Lisa Rojkjaer, M.D., as executive vice president and <a href="https://www.rigel.com/investors/news-events/press-releases/detail/382/rigel-pharmaceuticals-announces-appointment-of-lisa">chief medical officer</a>. Dr. Rojkjaer brings years of clinical development experience and should give Rigel investors hope.



Overall, Rigel has many exciting new developments and movements that could propel it to a whole new level this year. Investors don&rsquo;t want to miss the opportunity and should consider buying.



<h2>Eledon Pharmaceuticals (ELDN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Organ transplants are among the most complex medical procedures, even outside of the operating room. Many things must go right to ensure success. Eledon Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/eldn-stock-quote/">ELDN</a>) has made the success of organ transplants its mission and is developing the latest treatments in this field.



The company reported positive results in an <a href="https://ir.eledon.com/news-releases/news-release-details/eledon-presents-updated-data-ongoing-phase-1b-trial-evaluating">ongoing trial</a> for Eledon&rsquo;s product, Tegoprubart. The treatment is supposed to prevent rejection in kidney transplant patients. The company estimates that it will be finished enrolling patients for phase 2 of the trials for Tegoprubart by the end of the year.



Eledon reported an okay first quarter with a primarily flat net loss year-over-year but shared the exciting news of $50.0 million in <a href="https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-first-quarter-2024-operating-and">gross proceeds</a> from private placement financing. The company could be on the cusp of a major breakthrough in the coming years and is receiving cash from multiple outlets to support its continued research and development.&nbsp;



Investors can keep their eyes on Eledon as the chance to win big may be coming soon.



On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Joel Lim is a contributor at InvestorPlace.com and a finance content contractor who creates content for several companies like LTSE and Realtor, along with financial publications, including Business Insider, Yahoo Finance, Mises Institution and Foundation for Economic Education.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/penny-stock-picks-3-companies-poised-to-graduate-to-the-big-leagues/">Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues

Eledon Pharmaceuticals (ELDN) just unveiled an announcement. Eledon Pharmaceuticals, Inc. stockholders convened on July 10, 2024, approving key pro...

Eledon Pharmaceuticals Enacts Key Proposals and Board Changes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Wednesday morning!



Moving stocks are merger plans, a new contract, a CEO departure and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Gabelli Multi-Media Trust Inc. (The) Rights (expiring July 22, 2024) Rights (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGTR#NYSE">GGTR</a>) stock is rocketing 110% as the <a href="https://www.nasdaq.com/press-release/gabelli-multimedia-trust-alerts-common-stock-shareholders-rights-offering-expiration">rights offering expiration date closes in</a>.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are soaring more than 79% on an <a href="https://www.nasdaq.com/press-release/aditxt-and-evofem-amend-and-restate-merger-agreement-targeting-september-30-closing">amended merger agreement</a>.</li>



<li>Shimmick (NASDAQ:<a href="https://investorplace.com/stock-quotes/shim-stock-quote/">SHIM</a>) stock is surging over 56% on a <a href="https://www.marketwatch.com/story/shimmick-shares-surge-on-27-6-million-california-contract-121fe14b?mod=investing">$27.6 million contract</a>.</li>



<li>Aura Fat Projects (NASDAQ:<a href="https://investorplace.com/stock-quotes/afar-stock-quote/">AFAR</a>) shares are gaining more than 33% without any clear news this morning.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is increasing over 22% with heavy pre-market trading.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rising more than 18% with strong pre-market trading.</li>



<li>GitLab (NASDAQ:<a href="https://investorplace.com/stock-quotes/gtlb-stock-quote/">GTLB</a>) stock is climbing close to 16% higher on <a href="https://finance.yahoo.com/news/exclusive-google-backed-software-developer-060252892.html">reports it&rsquo;s considering a sale</a>.</li>



<li>Bloom Energy (NYSE:<a href="https://investorplace.com/stock-quotes/be-stock-quote/">BE</a>) shares are heading over 14% higher on a new <a href="https://finance.yahoo.com/news/bloom-energy-coreweave-partner-revolutionize-200500337.html">artificial intelligence (AI) data center partnership</a>.</li>



<li>Immersion (NASDAQ:<a href="https://investorplace.com/stock-quotes/immr-stock-quote/">IMMR</a>) stock is jumping nearly 12% this morning.</li>



<li>Eledon Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/eldn-stock-quote/">ELDN</a>) shares are up more than 11% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Five Below (NASDAQ:<a href="https://investorplace.com/stock-quotes/five-stock-quote/">FIVE</a>) stock is diving over 16% with the <a href="https://www.nasdaq.com/press-release/five-below-inc-announces-ceo-transition-2024-07-16">departure of its CEO</a>.</li>



<li>New Horizon Aircraft (NASDAQ:<a href="https://investorplace.com/stock-quotes/hovr-stock-quote/">HOVR</a>) shares are tumbling more than 13% after <a href="https://www.nasdaq.com/press-release/horizon-aircraft-attend-farnborough-international-airshow-2024-2024-07-15">rallying yesterday on airshow plans</a>.</li>



<li>QXO (NASDAQ:<a href="https://investorplace.com/stock-quotes/qxo-stock-quote/">QXO</a>) stock is taking an over 12% beating on Wednesday morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are sliding more than 12% after <a href="https://www.accesswire.com/888710/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-with-bank-islam-trust-company-labuan-ltd">jumping yesterday on strategic alliance news</a>.</li>



<li>Cineverse (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnvs-stock-quote/">CNVS</a>) stock is dropping over 10% on Wednesday.</li>



<li>Virpax Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrpx-stock-quote/">VRPX</a>) shares are decreasing almost 10% after rallying yesterday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is falling more than 9% after a similar rally yesterday.</li>



<li>Eightco (NASDAQ:<a href="https://investorplace.com/stock-quotes/octo-stock-quote/">OCTO</a>) shares are slipping over 9% <a href="https://www.stocktitan.net/news/OCTO/eightco-provides-shareholder-8okhfyrirfyb.html">following a shareholder update</a>.</li>



<li>Xeris Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/xers-stock-quote/">XERS</a>) stock is dipping more than 9% on Wednesday morning.</li>



<li>Logistic Properties of The Americas (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lpa-stock-quote/">LPA</a>) shares close out our pre-market stock movers down 9% after a recent rally.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report) today and set a price target of $...

Eledon Pharmaceuticals (ELDN) Receives a Buy from Noble Financial

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report) today and set a price target of $9...

Eledon Pharmaceuticals: A Strong Buy on Robust Financials and Promising Clinical Trials

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), with a price target of $7.00. ...

Eledon Pharmaceuticals: A Strong Buy on Clinical Progress and Strategic Positioning

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eledon Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/eldn-stock-quote/">ELDN</a>) just reported results for the second quarter of 2024.<ul><li>Eledon Pharma reported earnings per share of -$1.06. This was below the analyst estimate for EPS of -30 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eldn-stock-earnings-eledon-pharma-for-q2-of-2024/">ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price target of ...

Buy Rating Justified by Eledon Pharmaceuticals' Strategic Progress and Growth Potential

Eledon Pharmaceuticals (ELDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda...

Eledon Pharmaceuticals' Tegoprubart: A Strong Buy Based on Industry-Wide Validation and Promising Drug Data

ADTX

AFAR

APVO

CNVS

ELDN

FIVE

GGTR

GRNQ

GTLB

HOVR

IMMR

MLGO

OCTO

RIGL

SHIM

SOAR

TLRY

VRPX

XERS

Financing

Press Releases

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Health Care

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Comments

Eledon Pharma

Notizie

Ultime notizie per Eledon Pharma (NASDAQ:ELDN) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO